Note 9 - License Agreements (Details Textual) - USD ($)					1 Months Ended	3 Months Ended		159 Months Ended
	Feb. 10, 2025	Jan. 07, 2025	Jan. 07, 2024	Jul. 28, 2023	Dec. 31, 2012	Mar. 31, 2025	Mar. 31, 2024	Mar. 31, 2025	Dec. 31, 2024	Jan. 31, 2012
Income Tax Expense (Benefit)						$ 408,000	$ 29,000
Precision BioSciences, Inc. [Member]
Investment Purchased Balance Shares (in shares)		220,712	220,712
Investment Purchased Balance Price Per Share (in dollars per share)			$ 0.77
License Agreement, Share Price, Trading Days (Day)		30 days
Maximum [Member] | Precision BioSciences, Inc. [Member]
Investment Purchased Balance Shares (in shares)			2,920,816
L F B License Agreement [Member]
License And Collaboration Agreement, Expenses Incurred								$ 31,000,000
Accounts Payable						0		0
L F B License Agreement [Member] | License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)										15 years
Accrued Royalties						12,000,000		12,000,000
Sublicense Agreement With Ildong Pharmaceutical Co [Member]
Upfront Fee Received From Sub License					$ 2,000,000
Income Tax Expense (Benefit)					300,000
License Revenue						38,000	38,000
Deferred Revenue						100,000		100,000	$ 200,000
Additional Amount Receivable on Achievement of Pre-specified Milestones					$ 5,000,000
Sublicense Agreement With Ildong Pharmaceutical Co [Member] | License Agreement Terms [Member]
Finite-Lived Intangible Asset, Useful Life (Year)					15 years
Commercialization Agreement With Neuraxpharm [Member]
Deferred Revenue						23,700,000		23,700,000
Additional Amount Receivable on Achievement of Pre-specified Milestones				$ 492,500,000
License and Collaboration Agreements, One-time, Non-refundable Payment				$ 140,000,000		119,700,000
Royalty Percentage on Net Product Sales				30.00%
Agreement Buyback Period (Year)				2 years
Revenue, Remaining Performance Obligation, Amount						300,000		$ 300,000
Commercialization Agreement With Neuraxpharm [Member] | Royalty [Member]
Revenues						$ 600,000
Commercialization Agreement With Neuraxpharm [Member] | Royalty [Member] | Maximum [Member]
Revenues							$ 100,000
Briumvi Ublituximab [Member] | Product [Member]
Product Sales, Net Related to Performance Obligations				$ 12,500,000
Precision License Agreement [Member]
License Agreement, Amount Paid Upfront			$ 7,500,000
License Agreement, Amount Paid Upfront, Cash			5,250,000
License Agreement, Amount Paid Upfront, Equity Investment			2,250,000
License Agreement, Deferred Payment			$ 2,500,000
License Agreement, Percentage of Premium on Equity Investment			100.00%
License Agreement, Share Price, Trading Days (Day)			30 days
License Agreement, Additional Milestone Payments			$ 288,000,000
Term After First Commercial Sale (Year)			10 years
Strategic Platform License Agreement with MaxCyte, Inc. [Member]
License Agreement, Amount Paid Upfront	$ 1,000,000
License Agreement, Additional Milestone Payments	13,000,000
Licensing Agreement, Annual License Fee	$ 200,000
License Agreement, Term (Year)	10 years
License Agreement, Renewal Term (Year)	5 years
License Agreement, Written Notice Period (Day)	90 days